Tags

Type your tag names separated by a space and hit enter

Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group.
Circulation. 1993 Jun; 87(6 Suppl):VI111-7.Circ

Abstract

BACKGROUND

Advanced age is commonly thought to carry a poor prognosis in congestive heart failure, but the case has not been established. The Department of Veterans Affairs Cooperative Vasodilator-Heart Failure Trials (V-HeFT I and II) provided a large data base to assess the effect of age on hemodynamic profiles and survival in the failing heart.

METHODS AND RESULTS

Patients were stratified into four categories according to age: < or = 55, 56-60, 61-65, and > 65 years. The distributions of treatments and baseline characteristics from history, physical findings, and laboratory data were analyzed for differences across age categories. Survival curves were calculated for age strata according to treatment, presence or absence of coronary artery disease, ejection fraction, and peak oxygen consumption. Risk ratios for age and treatment categories showed no consistent trend of treatment effect on mortality. Age was significantly associated with coronary artery disease, hypertension, rhythm disturbances, systolic blood pressure, ejection fraction, and peak oxygen uptake, but successive age strata did not show incremental changes. Survival curves did not show progressively steeper slopes with advancing age. In V-HeFT I, the oldest patients did have the poorest survival, but age interacted with the presence of coronary artery disease and randomization into the placebo group.

CONCLUSIONS

Contrary to intuitive thinking, age alone did not shorten the survival in congestive heart failure patients who were < 75 years old and receiving optimal therapy.

Authors+Show Affiliations

Cardiac Rehabilitation Department, Veterans Affairs Medical Center, Milwaukee, Wis.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

8500234

Citation

Hughes, C V., et al. "Influence of Age On Mechanisms and Prognosis of Heart Failure. the V-HeFT VA Cooperative Studies Group." Circulation, vol. 87, no. 6 Suppl, 1993, pp. VI111-7.
Hughes CV, Wong M, Johnson G, et al. Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 Suppl):VI111-7.
Hughes, C. V., Wong, M., Johnson, G., & Cohn, J. N. (1993). Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group. Circulation, 87(6 Suppl), VI111-7.
Hughes CV, et al. Influence of Age On Mechanisms and Prognosis of Heart Failure. the V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 Suppl):VI111-7. PubMed PMID: 8500234.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Influence of age on mechanisms and prognosis of heart failure. The V-HeFT VA Cooperative Studies Group. AU - Hughes,C V, AU - Wong,M, AU - Johnson,G, AU - Cohn,J N, PY - 1993/6/1/pubmed PY - 1993/6/1/medline PY - 1993/6/1/entrez SP - VI111 EP - 7 JF - Circulation JO - Circulation VL - 87 IS - 6 Suppl N2 - BACKGROUND: Advanced age is commonly thought to carry a poor prognosis in congestive heart failure, but the case has not been established. The Department of Veterans Affairs Cooperative Vasodilator-Heart Failure Trials (V-HeFT I and II) provided a large data base to assess the effect of age on hemodynamic profiles and survival in the failing heart. METHODS AND RESULTS: Patients were stratified into four categories according to age: < or = 55, 56-60, 61-65, and > 65 years. The distributions of treatments and baseline characteristics from history, physical findings, and laboratory data were analyzed for differences across age categories. Survival curves were calculated for age strata according to treatment, presence or absence of coronary artery disease, ejection fraction, and peak oxygen consumption. Risk ratios for age and treatment categories showed no consistent trend of treatment effect on mortality. Age was significantly associated with coronary artery disease, hypertension, rhythm disturbances, systolic blood pressure, ejection fraction, and peak oxygen uptake, but successive age strata did not show incremental changes. Survival curves did not show progressively steeper slopes with advancing age. In V-HeFT I, the oldest patients did have the poorest survival, but age interacted with the presence of coronary artery disease and randomization into the placebo group. CONCLUSIONS: Contrary to intuitive thinking, age alone did not shorten the survival in congestive heart failure patients who were < 75 years old and receiving optimal therapy. SN - 0009-7322 UR - https://www.unboundmedicine.com/medline/citation/8500234/Influence_of_age_on_mechanisms_and_prognosis_of_heart_failure__The_V_HeFT_VA_Cooperative_Studies_Group_ L2 - https://medlineplus.gov/heartfailure.html DB - PRIME DP - Unbound Medicine ER -